Provided by Tiger Fintech (Singapore) Pte. Ltd.

Esperion Therapeutics

0.8520
-0.0980-10.32%
Pre-market: 0.90000.0480+5.63%04:12 EDT
Volume:5.90M
Turnover:5.10M
Market Cap:168.57M
PE:-3.08
High:0.9332
Open:0.9300
Low:0.8191
Close:0.9500
Loading ...

Company Profile

Company Name:
Esperion Therapeutics
Exchange:
NASDAQ
Establishment Date:
2008
Employees:
304
Office Location:
3891 Ranchero Drive,Suite 150,Ann Arbor,Michigan,United States
Zip Code:
48108
Fax:
- -
Introduction:
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Directors

Name
Position
Tim M. Mayleben
Director, President and Chief Executive Officer
Alan Fuhrman
Indepdendent Director
Antonio M. Gotto Jr.
Indepdendent Director
Daniel S. Janney
Indepdendent Director
Jay P. Shepard
Indepdendent Director
Mark E. McGovern
Indepdendent Director
Nicole Vitullo
Lead Independent Director
Tracy M. Woody
Indepdendent Director
Jeffrey Berkowitz
Director

Shareholders

Name
Position
Tim M. Mayleben
Director, President and Chief Executive Officer
Richard B. Bartram
Chief Financial Officer
Ashley Hall
Chief Development Officer
Mark Glickman
Chief Commercial Officer